Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mitocin 20mg powder for solution for injection vials
0801020Q0BCAAAG
|
Mitocin | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin 10mg powder for solution for injection vials
0801020Q0AAAFAF
|
Mitomycin | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin 20mg powder for solution for injection vials
0801020Q0AAAGAG
|
Mitomycin | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin 2mg powder for solution for injection vials
0801020Q0AAAEAE
|
Mitomycin | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin 40mg powder for intravesical solution vials
0801020Q0AAADAD
|
Mitomycin | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin-C Kyowa 10mg inj vials
0801020Q0BBABAF
|
Mitomycin-C Kyowa | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin-C Kyowa 20mg inj vials
0801020Q0BBACAG
|
Mitomycin-C Kyowa | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin-C Kyowa 2mg inj vials
0801020Q0BBAAAE
|
Mitomycin-C Kyowa | Mitomycin | Malignant Disease and Immunosuppression | No data available |
|
Mitomycin-C Kyowa 40mg pdr for intravesical solution vials
0801020Q0BBADAD
|
Mitomycin-C Kyowa | Mitomycin | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.